PLoS ONEBioinformaticsPeer-reviewed journal article
EUAdb: a resource for COVID-19 test development
Alyssa WoronikiD, Henry W. Shaffer, Karin C. KiontkeiD, Jon M. LaurentiD, Ronald ZambranoiD, Mariah DaleyiD, Jef D. BoekeiD, David H. A. FitchiD
Abstract
Due to the sheer number of COVID-19 (coronavirus disease 2019) cases, the prevalence of asymptomatic cases and the fact that undocumented cases appear to be significant for transmission of the causal virus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), there is an urgent need for increased SARS-CoV-2 testing capability that is both efficient and effective1. In response to the growing threat of the COVID-19 pandemic in February, 2020, the FDA (US Food and Drug Administration) began issuing Emergency Use Authorizations (EUAs) to laboratories and commercial manufacturers for the development and implementation of diagnostic tests1. So far, the gold standard assay for SARS-CoV-2 detection is the RT-qPCR (real-time quantitative polymerase chain reaction) test2. However, the authorized RT-qPCR test protocols vary widely, not only in the reagents, controls, and instruments they use, but also in the SARS-CoV-2 genes they target, what results constitute a positive SARS-CoV-2 infection, and their limit of detection (LoD). The FDA has provided a web site that lists most of the tests that have been issued EUAs, along with links to the authorization letters and summary documents describing these tests1. However, it is very challenging to use this site to compare or replicate these tests for a variety of reasons. First, at least 12 of 18 tests for EUA submissions made prior to March 31, 2020, are not listed there. To our knowledge, no EUAs have been issued for these applications. Second, the data are not standardized and are only provided as longhand prose in the summary documents. Third, some details (e.g. primer sequences) are absent from several of the test descriptions. Fourth, for tests provided by commercial manufacturers, summary documents are completely missing. To address at least the first three issues, we have developed a database, EUAdb (EUAdb.org), that holds standardized information about EUA-issued tests and is focused on RT-qPCR diagnostic tests, or "high complexity molecular-based laboratory developed tests"1. By providing a standardized ontology and curated data in a relational architecture, we seek to facilitate comparability and reproducibility, with the ultimate goal of consistent, universal and high-quality testing nationwide. Here, we document the basics of the EUAdb data architecture and simple data queries. The source files can be provided to anyone who wants to modify the database for his/her own research purposes. We ask that the original source of the files be made clear and that the database not be used in its original or modified forms for commercial purposes.
- Citations
- 1
- FWCI
- 0.08
- Field percentile
- 44th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comparison of the NeuMoDX, Diasorin Simplexa, Cepheid and Roche CDC SARS-CoV 2 EUA assays using nasopharyngeal/nasal swabs in universal transport media (UTM) and sputum and tracheal aspirates
R. J. Tibbetts, K. Callahan, … L. P. Samuel·bioRxiv·May 26, 2020
- A Rapid COVID-19 RT-PCR Detection Assay for Low Resource Settings
Arunkumar Arumugam, Matthew L. Faron, … Season Wong·DiagnosticsPeer-reviewed·Sep 24, 2020
- Analytical and Clinical Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection
E. Smith, W. Zhen, … G. J. Berry·bioRxiv·May 14, 2020
- An Inexpensive RT-PCR Endpoint Diagnostic Assay for SARS-CoV-2 Using Nested PCR: Direct Assessment of Detection Efficiency of RT-qPCR Tests and Suitability for Surveillance
Jayeshkumar Narsibhai Davda, Keith Frank, … Imran Siddiqi·bioRxiv·Jun 8, 2020
- Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic
Paul R. Grant, Melanie Turner, … Lisa J. Levett·bioRxiv·Apr 6, 2020
- Validation and performance of a quantitative IgG assay for the screening of SARS-CoV-2 antibodies
A. M. Espino, P. Pantoja, C. A. Sariol·bioRxiv·Jun 11, 2020